



AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@amd.com
(Tel :) 206.310.5323

FOR IMMEDIATE RELEASE

AMDL INC.'S JJB PLANT RECEIVES PRODUCTION APPROVAL FROM CHINESE STATE FOOD AND DRUG ADMINISTRATION

(TUSTIN, CA) May 8, 2009/PRNewswire – [AMDL Inc.](#) (NYSE Alternext US: [ADL](#) - [News](#)), a US-based pharmaceutical company with major operations in China, announced today it has received approval from the Chinese State Food and Drug Administration (sFDA) to re-initiate product production on a small injectable manufacturing line housed at the Company's Jiangxi JieXhong Pharmaceutical Co. (JJB) wholly foreign-owned subsidiary located in Shangrao, Jiangxi Province, China. The re-certified manufacturing line is used to manufacture AMDL's Goodnak® anti-aging injectable product and other small volume parenteral solutions.

The sFDA requires all China-based facilities engaged in the manufacture of pharmaceutical products to have "Good Manufacturing Practices" (GMP) certification. In Q108, JJB's GMP certification expired for the small volume parenteral solutions injection lines and the Company initiated \$1.5 million in renovations to bring the line into compliance with the SFDA. With today's announcement, JJB has re-opened its Jiangxi-based production line and resumed operations for the small injectable manufacturing line, including production of AMDL's best-selling Goodnak anti-aging injectable product and other small volume parenteral solutions.

According to Mr. Douglas MacLellan, Chairman and CEO of AMDL Inc., "Our small volume injectables production line at JJB has resumed operations and we are currently manufacturing new Goodnak product. Sales are anticipated to resume in earnest by May 15th and AMDL remains on track with its quarterly and fiscal year business and financial projections."

For additional information on AMDL, its FY09 financial forecast, portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at kszarkowitz@amd.com.

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be

considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###